Have your own idea? Try our Stock Screener
Swedish (OMX) Biotech Industry Analysis
UpdatedDec 21, 2024
DataAggregated Company Financials
Companies62
- 7D1.2%
- 3M-0.3%
- 1Y13.8%
- YTD11.4%
The Biotech industry is up 1.2% in the last week, with BioArctic up 24%. This means that the industry has gained 14% over the past year. Looking forward, earnings are forecast to grow by 45% annually.
Industry Valuation and Performance
Has the Swedish Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 22 Dec 2024 | SEK 215.0b | SEK 33.0b | -SEK 4,423,168,415.46 | 155.2x | -48.6x | 6.5x |
| Tue, 19 Nov 2024 | SEK 205.4b | SEK 33.0b | -SEK 4,537,816,044.08 | 141.7x | -45.3x | 6.2x |
| Thu, 17 Oct 2024 | SEK 205.9b | SEK 31.4b | -SEK 5,536,461,899.55 | 47.5x | -37.2x | 6.5x |
| Sat, 14 Sep 2024 | SEK 218.6b | SEK 31.5b | -SEK 5,518,169,191.21 | 52.2x | -39.6x | 6.9x |
| Mon, 12 Aug 2024 | SEK 195.0b | SEK 31.4b | -SEK 5,206,863,894.03 | 44.5x | -37.5x | 6.2x |
| Wed, 10 Jul 2024 | SEK 195.8b | SEK 30.6b | -SEK 5,534,908,880.89 | 39.1x | -35.4x | 6.4x |
| Fri, 07 Jun 2024 | SEK 199.4b | SEK 30.6b | -SEK 5,380,259,285.24 | 40x | -37.1x | 6.5x |
| Sun, 05 May 2024 | SEK 184.9b | SEK 31.0b | -SEK 5,452,001,822.35 | 50.4x | -33.9x | 6x |
| Tue, 02 Apr 2024 | SEK 185.5b | SEK 29.8b | -SEK 5,642,566,436.15 | 60.5x | -32.9x | 6.2x |
| Thu, 29 Feb 2024 | SEK 176.7b | SEK 29.8b | -SEK 5,648,485,462.18 | 54.4x | -31.3x | 5.9x |
| Sat, 27 Jan 2024 | SEK 187.5b | SEK 28.7b | -SEK 1,197,493,822.00 | 60.8x | -156.6x | 6.5x |
| Mon, 25 Dec 2023 | SEK 181.8b | SEK 28.7b | -SEK 1,195,731,362.00 | 60.6x | -152x | 6.3x |
| Wed, 22 Nov 2023 | SEK 167.6b | SEK 28.7b | -SEK 1,186,816,677.00 | 54.5x | -141.2x | 5.8x |
| Fri, 20 Oct 2023 | SEK 150.0b | SEK 27.4b | -SEK 1,976,849,847.00 | 47.2x | -75.9x | 5.5x |
| Sun, 17 Sep 2023 | SEK 154.2b | SEK 27.4b | -SEK 1,977,805,956.00 | 50.6x | -78x | 5.6x |
| Tue, 15 Aug 2023 | SEK 159.9b | SEK 27.6b | -SEK 1,573,556,553.00 | 54.6x | -101.6x | 5.8x |
| Thu, 13 Jul 2023 | SEK 159.4b | SEK 26.4b | -SEK 1,365,321,325.00 | 44.7x | -116.7x | 6x |
| Sat, 10 Jun 2023 | SEK 171.6b | SEK 26.4b | -SEK 1,234,659,624.00 | 45.9x | -139x | 6.5x |
| Mon, 08 May 2023 | SEK 179.4b | SEK 26.3b | -SEK 1,156,124,007.00 | 46.2x | -155.1x | 6.8x |
| Wed, 05 Apr 2023 | SEK 166.3b | SEK 25.4b | -SEK 2,016,291,208.00 | 38.2x | -82.5x | 6.6x |
| Fri, 03 Mar 2023 | SEK 171.2b | SEK 25.4b | -SEK 2,050,595,594.00 | 39.9x | -83.5x | 6.7x |
| Sun, 29 Jan 2023 | SEK 175.8b | SEK 23.8b | -SEK 1,837,825,591.00 | 31.2x | -95.7x | 7.4x |
| Tue, 27 Dec 2022 | SEK 156.7b | SEK 23.8b | -SEK 1,842,897,823.00 | 31.4x | -85x | 6.6x |
| Thu, 24 Nov 2022 | SEK 157.7b | SEK 23.8b | -SEK 1,837,397,506.00 | 31.1x | -85.8x | 6.6x |
| Sat, 22 Oct 2022 | SEK 148.2b | SEK 23.3b | -SEK 3,159,299,885.00 | 32.9x | -46.9x | 6.4x |
| Mon, 19 Sep 2022 | SEK 149.0b | SEK 22.9b | -SEK 3,316,789,732.00 | 32.2x | -44.9x | 6.5x |
| Wed, 17 Aug 2022 | SEK 171.6b | SEK 22.6b | -SEK 3,543,585,564.00 | 34.9x | -48.4x | 7.6x |
| Fri, 15 Jul 2022 | SEK 158.0b | SEK 21.4b | -SEK 3,541,064,530.00 | 39.1x | -44.6x | 7.4x |
| Sun, 12 Jun 2022 | SEK 152.3b | SEK 21.4b | -SEK 3,526,521,715.00 | 39.7x | -43.2x | 7.1x |
| Tue, 10 May 2022 | SEK 138.1b | SEK 21.4b | -SEK 3,352,515,372.00 | 44.6x | -41.2x | 6.5x |
| Thu, 07 Apr 2022 | SEK 178.3b | SEK 19.7b | -SEK 3,200,377,017.00 | 50.6x | -55.7x | 9.1x |
| Sat, 05 Mar 2022 | SEK 150.6b | SEK 19.6b | -SEK 3,006,846,242.00 | 49.7x | -50.1x | 7.7x |
| Mon, 31 Jan 2022 | SEK 165.3b | SEK 19.1b | -SEK 2,193,425,487.00 | 52.5x | -75.4x | 8.7x |
| Wed, 29 Dec 2021 | SEK 201.7b | SEK 19.1b | -SEK 2,003,568,087.00 | 52.9x | -100.7x | 10.6x |
Price to Earnings Ratio
-100.7x
Current Industry PE
- Investors are relatively neutral on the Swedish Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.8x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 20% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Swedish Healthcare industry?
| SE Market | -2.70% | |
| Healthcare | 0.53% | |
| Biotech | 1.25% | |
| Biotech | 1.25% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BIOA B BioArctic | SEK 212.80 | 23.9% +SEK 3.6b | -21.2% | PS112.5x | |
| BONEX Bonesupport Holding | SEK 382.00 | 8.0% +SEK 1.9b | 108.7% | PE277.5x | |
| HNSA Hansa Biopharma | SEK 38.88 | 32.3% +SEK 644.2m | 57.7% | PS13.9x | |
| ABLI Abliva | SEK 0.42 | 204.4% +SEK 454.1m | 69.8% | PS4935.7x | |
| SANION Saniona | SEK 8.12 | 14.5% +SEK 115.2m | 116.5% | PS34.1x |